The many sides of off-label prescribing

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 5, 2012, Pages 755-758

  Epstein, R S ^a   Huang, S M ^b  

^a Medco Health Solutions   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIALLERGIC AGENT; ANTIASTHMATIC AGENT; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; PRESCRIPTION DRUG;

DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; OFF LABEL DRUG USE; PRESCRIPTION; PRIORITY JOURNAL;

DRUG LABELING; HUMANS; OFF-LABEL USE; PERIODICALS AS TOPIC;

EID: 84859933889     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.37     Document Type: Editorial

References (14)

1. Avorn, J. & Shrank, W. Highlights and a hidden hazard - the FDA's new labeling regulations. N. Engl. J. Med. 354, 2409-2411 (2006).
2. US Food and Drug Administration. Requirements on content and format of labeling for human prescription drug and biological products. Final Rule 〈http://www. fda.gov/OHRMS/DOCKETS/98fr/06-545.pdf〉 (24 January 2006).
3. US Food and Drug Administration. Medical, statistical, and clinical pharmacology reviews of pediatric studies conducted under section 505A and 505B of the Federal Food, Drug, and Cosmetic Act, as amended by the FDA Amendments Act of 2007 (FDAAA). 〈http:// www.fda.gov/Drugs/DevelopmentApprovalProcess/ DevelopmentResources/UCM049872〉 (2011).
4. Radley, D., Finkelstein, S. & Stafford, R.S. Off-label prescribing among office-based physicians. Arch. Intern. Med. 166, 1021-1026 (2006).
5. Stafford, R.S. Off-label use of drugs and medical devices: a review of policy implications. Clin. Pharmacol. Ther. 91, 920-925 (2012)
6. Kimland, E. & Odlind, V. Off-label drug use in pediatric patients. Clin. Pharmacol. Ther. 91, 796-801 (2012).
7. Dal Pan, G.J. Monitoring the safety of medicines used off-label. Clin. Pharmacol. Ther. 91, 787-795 (2012).
8. Morris, J. The use of observational health-care data to identify and report on off-label use of biopharmaceutical products. Clin. Pharmacol. Ther. 91, 937-942 (2012).
9. Leong, R. et al. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin. Pharmacol. Ther. 91, 926-931 (2012).
10. Bashaw, E.D. et al. Clinical pharmacology as a cornerstone of orphan drug development. Nat. Rev. Drug Discov. 10, 795-796 (2011).
11. Bashaw, E.D. & Fang, L. Clinical pharmacology and orphan drugs: an informational inventory 2006-2010. Clin. Pharmacol. Ther. 91, 932-936 (2012).
12. Stanek, E.J. et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin. Pharmacol. Ther. 91, 450-458 (2012).
13. Teagarden, J.R., Dreitlein, W.B., Kourlas, H. & Nichols, L. Influence of pharmacy benefit practices on off-label dispensing of drugs in the United States. Clin. Pharmacol. Ther. 91, 943-945 (2012).
14. Fotsch, E.J. Electronic health records: the new vehicle for drug labeling, safety, and efficacy. Clin. Pharmacol. Ther. 91, 917-919 (2012).